Senseonics Holdings (SENS) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Senseonics Holdings (SENS) right now is Eversense 365 one-year differentiation: Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. Full-year 2025 revenue is ~$35.3M (up from ~$22.5M in 2024). If that keeps playing out, the setup is favourable; the risk to it is senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. No one can predict where SENS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Senseonics Holdings (SENS) higher?
Eversense 365 one-year differentiation
Eversense 365 extends sensor life to a full year, a meaningfully different experience from the 10-to-15-day disposable patches sold by larger competitors. Fewer replacements and an implantable form factor give the product a distinct position with users who want less frequent maintenance, and management has tied recent growth in new patient starts and improving gross margin to 365 adoption.
Bringing commercialization in-house from Ascensia
Eversense was historically distributed through a partnership with Ascensia Diabetes Care. Senseonics has been transitioning commercial, sales, and distribution rights back in-house in both the U.S. and Europe. Eliminating the revenue share with Ascensia is intended to lift gross margin and give the company direct control of marketing, though it also adds operating expense as it builds that infrastructure.
A large and growing CGM market
Continuous glucose monitoring continues to expand as use spreads beyond insulin-dependent diabetes toward broader type 2 and prediabetes populations. Senseonics is also pursuing automated insulin delivery (AID) integrations and a next-generation sensor program. A small share of a large, growing category is the bull framing, but capturing it requires execution against entrenched incumbents.
Margin and revenue inflection underway
Reported revenue grew sharply in 2025 and into 2026 as Eversense 365 ramped and the Ascensia revenue share rolled off, with gross margin improving from near breakeven. Management raised full-year 2026 revenue guidance, signaling confidence in the trajectory, though the business is still operating at a substantial net loss.
What could weigh on SENS?
Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty.
How to think about a SENS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the SENS guide and whether SENS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the SENS outlook
The bottom line: what is driving Senseonics Holdings (SENS) is Eversense 365 one-year differentiation, with full-year 2025 revenue at ~$35.3M (up from ~$22.5M in 2024). If that keeps playing out the setup is favourable; the risk is senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. No one can predict the price, so treat any SENS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around SENS with Walnut
Use Senseonics Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Senseonics Holdings (SENS)?
+
No one can reliably predict where SENS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Senseonics Holdings higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive SENS higher?
+
The main growth drivers are Eversense 365 one-year differentiation; Bringing commercialization in-house from Ascensia; A large and growing CGM market. Whether they play out is the real question, not a guaranteed path.
What are the risks to SENS?
+
Senseonics competes against Dexcom and Abbott, both far larger, profitable, and better capitalized, and either can press on price, reimbursement access, or product cadence. Scale is small, so a single reimbursement decision, manufacturing issue, or slower-than-expected patient adoption can move results materially. The company remains unprofitable and burns cash, so it has relied on equity and debt financing that can dilute shareholders. Reimbursement and regulatory outcomes across the U.S. and Europe add further uncertainty.
Will SENS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Senseonics Holdings's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is SENS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the SENS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.